Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001013594-26-000256·Keros Therapeutics, Inc.
Schedule 13G ownership disclosure
Keros Therapeutics Inc
Common Stock, $0.0001 par value per share (the "Common Stock") · CUSIP: 492327101
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Madison Avenue International LP
Shares: 823,707 · Class: 2.7%
- Madison Avenue Partners, LP
Shares: 823,707 · Class: 2.7%
- EMAI Management, LLC
Shares: 823,707 · Class: 2.7%
- Madison Avenue GP, LLC
Shares: 823,707 · Class: 2.7%
- Caraway Jackson Investments LLC
Shares: 823,707 · Class: 2.7%
- Eli Samaha
Shares: 823,707 · Class: 2.7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001013594-26-000256
- Form type
- SCHEDULE 13G/A
- Filer
- Keros Therapeutics, Inc.
- CIK
- CIK 1664710
- Filed
- Feb 17, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership